Healthcare Equipment and Supplies
Company Overview of bioLytical Laboratories Inc.
bioLytical Laboratories Inc. develops and manufactures diagnostic products. It provides INSTI, a HIV-1/HIV-2 rapid antibody test used for the detection of antibodies to human immunodeficiency virus type 1 in human whole blood, serum, or plasma. The company sells its products through distributors in Canada and India. bioLytical Laboratories Inc. was founded in 2002 and is based in Richmond, Canada.
1108 - 13351 Commerce Parkway
Richmond, BC V6V 2X7
Founded in 2002
Key Executives for bioLytical Laboratories Inc.
Chief Technical Officer and Vice President
Director of Automation and Materials
Director of Regulatory Affairs
Compensation as of Fiscal Year 2016.
bioLytical Laboratories Inc. Key Developments
Biolytical Laboratories Announces Patent Filings in U.S. for Zika Detection Assays
Aug 19 16
bioLytical Laboratories announced that it has filed two patent applications with the U.S. Patent and Trademark Office relating to multiple color rapid detection assay systems. The two new patent applications expand the growing intellectual property portfolio for the company and the innovative features that make this an ideal immunoassay system for the detection of antibodies to pathogens including Zika and other flaviviruses. The two new patent applications are based on the Company's INSTI platform and describe methods and kits allowing either simultaneous or sequential detection of different antibody classes to multiple pathogens using a single sample of blood or blood product. The first patent application describes a method for detecting active or past infection using Zika as an example. The second patent application describes a method for differentiating early from later stages of infection. These technology breakthroughs can revolutionize point-of-care rapid assays for detection of acute infections including Zika.
bioLytical Laboratories Inc.'s INSTI HIV Test Detects gp41 Specific IgM Antibodies
Sep 3 15
bioLytical Laboratories Inc. announce its study 'Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its affinity for HIV gp41 IgM antibodies has been published in the Journal of Clinical Virology. This study highlights INSTI's ability to detect early HIV infection. BioLytical researchers presented their findings at the 8th annual International AIDS Society Conference, which highlighted early HIV detection using INSTI HIV-1/HIV-2 Antibody Test. The study demonstrated that both recombinant gp41 antigen and protein-A in the HIV screening assay have affinity to human IgM. When IgM was removed from early seroconversion samples that were once reactive with INSTI, the results were non-reactive or barely reactive. The study concluded that INSTI can detect anti-HIV-1 IgM antibodies, which enhances its utility in early HIV diagnosis. Early detection provides significant advantage in the fight against HIV/AIDS. INSTI HIV-1/HIV-2 Antibody Test's ability to detect early HIV antibodies is key to providing earlier diagnosis leads to earlier treatment.
bioLytical Laboratories Develops 60-Second Ebola Testing Kit
Oct 29 14
bioLytical Laboratories has successfully developed a pre-clinical prototype diagnostic test for the rapid detection of antibodies to the Ebola Zaire strain responsible for the current outbreak in West Africa. The prototype is based upon the company's proven, accurate, and highly accepted INSTI rapid test platform, which is capable of providing results in as little as 60 seconds.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries